描述
Powered by Eupheria Biotech
品質等級
產品線
MISSION®
形狀
lyophilized powder
esiRNA cDNA 標靶序列
CTGCTGCTGCTGATGGAATAATCCGAGTGCAGCCTAAATCGGAGCTCAAGCCTGGTGACGTTAAGCCACTGAGCAAGGATGATTTGGGTCTGCATGCCTACAGGTGTGAGGACTGCGGCAAGTGCAAGTGTAAGGAGTGCACCTACCCGAGGCCCCTGCCGTCGGACTGGATCTGTGACAAGCAGTGCCTCTGCTCAGCCCAGAACGTCATTGACTATGGGACTTGTGTGTGCTGTGTGAAAGGTCTCTTCTATCACTGCTCCAATGACGATGAGGACAATTGTGCTGACAACCCGTGCTCTTGCAGCCAGTCCCATTGTTGTACGCGATGGTCAGCGATGGGAGTCATGTCTCTCTTTTTGCCTTGTTTATGGTGTTACCTTCCAGCCAAGGGTTGCCTTAAATTGTGCCAGGGGTGTT
Ensembl | 小鼠類登錄號
NCBI登錄號
運輸包裝
ambient
儲存溫度
−20°C
基因資訊
mouse ... SPRY2(24064) , Spry2(24064)
一般說明
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
法律資訊
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到適合的產品？
試用我們的產品選擇工具.
儲存類別代碼
10 - Combustible liquids
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Jun-Ho Ahn et al.
Biomolecules & therapeutics, 23(4), 320-326 (2015-07-15)
The clinical benefits of oncogenic BRAF inhibitor therapies are limited by the emergence of drug resistance. In this study, we investigated the role of a negative regulator of the MAPK pathway, Spry2, in acquired resistance using BRAF inhibitor-resistant derivatives of
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務